Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunrest LifescienceNSE:SUNREST 42 Cash Ratio is 0.09 as of Mar. 2026, which is 80% above its 10-year median of 0.05. GuruFocus rates NSE:SUNREST with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Sunrest Lifescience ranks worse than 88.46% on this metric.
Sunrest Lifescience has a Cash Ratio of 0.09. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Sunrest Lifescience's Cash Ratio or its related term are showing as below:
NSE:SUNREST'
s Cash Ratio Range Over the Past 10 Years
Min: 0.04 Med: 0.05 Max: 0.09
Current: 0.09
During the past 7 years, Sunrest Lifescience's highest Cash Ratio was 0.09. The lowest was 0.04. And the median was 0.05.
NSE:SUNREST's Cash Ratio is ranked worse than 88.46% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 0.57
vs NSE:SUNREST: 0.09
Sunrest Lifescience (NSE:SUNREST) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Sunrest Lifescience Cash Ratio Related Terms
Sunrest Lifescience Cash Ratio Historical Data
* Premium members only.
The historical data trend for Sunrest Lifescience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience Cash Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience (NSE:SUNREST) has a Cash Ratio of 0.09 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sunrest Lifescience and its competitors. This is 80% above median its historical median of 0.05. Over the past decade, Sunrest Lifescience's Cash Ratio has ranged from 0.04 to 0.09. According to the industry distribution chart, Sunrest Lifescience ranks #590 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 88.5%.
Is Sunrest Lifescience's Cash Ratio too high?
Sunrest Lifescience's current Cash Ratio of 0.09 is 80% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.09. The Healthcare Providers & Services industry median Cash Ratio is 0.57. Sunrest Lifescience's value of 0.09 is 84.2% below this industry median. Based on the distribution chart, Sunrest Lifescience ranks #590 out of 667 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Sunrest Lifescience has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's Cash Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #590 out of 667 companies for Cash Ratio. This places Sunrest Lifescience in the lower half of its industry. The industry median Cash Ratio is 0.57. Sunrest Lifescience's value of 0.09 is 84.2% below this benchmark. Historically, Sunrest Lifescience's own Cash Ratio has ranged from 0.04 to 0.09 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.57, Sunrest Lifescience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.57, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current Cash Ratio of 0.09 is 84.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sunrest Lifescience and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current Cash Ratio is 0.09, which is 80% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current Cash Ratio of 0.09. The current Cash Ratio is 0.09, which is 80% above median its 10-year median of 0.05 and 84.2% below the Healthcare Providers & Services industry median of 0.57. Sunrest Lifescience's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current Cash Ratio is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
42GF Score
Get the complete analysis for NSE:SUNREST
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
